MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
Architects: Biotechnology_CAR-T (Chimeric Antigen Receptors-T Cell), T Cell Engager (TCE) & T-Cell Research
Cellectis BioResearch SA (NASDAQ: CLLS)
Organization & Developments: Cellectis
Parents
Cellectis BioResearch SA (NASDAQ: CLLS)
Children
*CAR-T Therapy
2012: Cellectis BioResearch Wins a $6 9 Million Contract from NIH (2012)
2016: Juno slammed on suspension of mid-stage study of lead product candidate JCAR015; shares down 28% premarket - Juno Therapeutics (NASDAQ:JUNO)
2017: Cellectis: The Next And Definitive Wave Of CAR-T - Cellectis S.A. (NASDAQ:CLLS)
2019: Cellectis Details Proof-of-Concept for "Smart" CAR T-Cells
2020: Cellectis Reports Clinical Hold Placed on MELANI-01 Study Paris Stock Exchange:ALCLS
2020: Time To Slowly Scale In To Cellectis - Cellectis S.A. (NASDAQ:CLLS)
2020: Why This Biotech Stock Is Planning To Gene Edit Its Cancer Drugs_www.investors.com
2023: Cellectis: End Of 2023 Data Readouts To Boost CAR-T Prospects_ seekingalpha.com
2024: Cellectis: Poised To Start Answering Questions In 2025
2024: Cellectis: Pushing A Different Kind Of CAR-T Up The Hill_seekingalpha.com
2025:Cellectis: Partnerships And Promised Data In 2025 Continue To Justify The Buy
Jumps
*Key People: Cellectis
Finance & Acquisitions: Cellectis